213896-18-5Relevant academic research and scientific papers
Receptor Antagonists
-
, (2008/06/13)
The present invention provides an α2c-adrenoceptor antagonist comprising, as an active ingredient, a condensed-ring-pyrimidine derivative represented by general formula (I) below or a pharmaceutically acceptable salt thereof useful for treating and/or preventing various diseases induced by hyperactivity of α2c-adrenoceptor (for example, Parkinson's disease, L-DOPA-induced dyskinesia, tardive dyskinesia and depression) and the like. {wherein p represents an integer of 1 to 3; R1 represents a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aryl, or the like; R2 represents —N(—R4)(—R5) (wherein R4 and R5 are the same or different, and each represents a hydrogen atom, substituted or unsubstituted aralkyl, or the like, or R4 and R5 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or the like; and -Q- represents —N═C(—R7)— [wherein R7 represents —N(—R9)(—R10) (wherein R9 and R10 are the same or different, and each represents substituted or unsubstituted aralkyl, or the like, or R9 and R10 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or the like] or the like}
[1,2,4] triazolo [1,5-C] pyrimidine derivatives
-
, (2008/06/13)
[1,2,4]Triazolo[1,5-c]pyrimidine derivatives represented by formula (I) or pharmaceutically acceptable salts thereof are provided, which have adenosine A2Areceptor antagonism and are useful for the treatment or prevention of various diseases in
